Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

StemRIM (4599)

Tokyo
Currency in JPY
Disclaimer
424.0
-14.0(-3.19%)
Closed
4599 Scorecard
Trading near 52-week Low
Fair Value
Unlock Value
Day's Range
419.0440.0
52 wk Range
419.01,320.0
Bid/Ask
424.00 / 425.00
Prev. Close
439
Open
438
Day's Range
419-440
52 wk Range
419-1,320
Volume
145,100
Average Volume (3m)
278,744
1-Year Change
-67.46%
Shares Outstanding
61,469,679
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
How do you feel today about 4599?
Vote to see community's results!
or
  • StemRIM Earnings beat, Revenue Inline In Q4
    • ByInvesting.com

StemRIM Company Profile

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Employees
45
Market
Japan
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.